J Prandota

1.6k total citations · 1 hit paper
61 papers, 1.2k citations indexed

About

J Prandota is a scholar working on Pediatrics, Perinatology and Child Health, Pharmacology and Molecular Biology. According to data from OpenAlex, J Prandota has authored 61 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pediatrics, Perinatology and Child Health, 14 papers in Pharmacology and 13 papers in Molecular Biology. Recurrent topics in J Prandota's work include Toxoplasma gondii Research Studies (9 papers), Pharmaceutical studies and practices (9 papers) and Antibiotics Pharmacokinetics and Efficacy (8 papers). J Prandota is often cited by papers focused on Toxoplasma gondii Research Studies (9 papers), Pharmaceutical studies and practices (9 papers) and Antibiotics Pharmacokinetics and Efficacy (8 papers). J Prandota collaborates with scholars based in Poland, United States and United Kingdom. J Prandota's co-authors include Zafar H. Israili, Jaroslav Flegr, Albert W. Pruitt, P d'Athis, J P Tillement, J. Barré, John T. Wilson, Georges Houin, I. J. Smith and Leszek Noga and has published in prestigious journals such as PLoS ONE, Acta Biomaterialia and The Pediatric Infectious Disease Journal.

In The Last Decade

J Prandota

60 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Toxoplasmosis – A Global Threat. Correlation of Latent Toxoplasmosis with Specific Disease Burden in a Set of 88 Countries

2014 494 citations Jaroslav Flegr, J Prandota et al. PLoS ONE profile →

Peers

Countries citing papers authored by J Prandota

Since Specialization

Citations

This map shows the geographic impact of J Prandota's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J Prandota with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J Prandota more than expected).

Fields of papers citing papers by J Prandota

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J Prandota. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J Prandota. The network helps show where J Prandota may publish in the future.

Co-authorship network of co-authors of J Prandota

This figure shows the co-authorship network connecting the top 25 collaborators of J Prandota. A scholar is included among the top collaborators of J Prandota based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J Prandota. J Prandota is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	3D-printed polycaprolactone scaffolds functionalized with poly(lactic-co-glycolic) acid microparticles enhance bone regeneration through tunable drug release 2025 ·Acta Biomaterialia ·(unknown), (unknown), María Cristina Martínez-Ohárriz, Purificación Ripalda‐Cemboráin, (unknown), Gloria Abizanda, (unknown), J Prandota, (unknown), Elisa Garbayo, Felipe Prósper, María Jimena Prieto, Froilán Granero‐Moltó	4
2	Possible Pivotal Role of Latent Chronic T. gondii Infection in the Pathogenesis of Atherosclerosis 2017 ·J Prandota	1
3	Toxoplasmosis – A Global Threat. Correlation of Latent Toxoplasmosis with Specific Disease Burden in a Set of 88 Countries breakdown → 2014 ·PLoS ONE ·Jaroslav Flegr, J Prandota, (unknown), Zafar H. Israili	494
4	Migraine Associated with Patent Foramen Ovale May Be Caused by Reactivation of Cerebral Toxoplasmosis Triggered by Arterial Blood Oxygen Desaturation 2010 ·International Journal of Neuroscience ·J Prandota	25
5	Advances of Molecular Clinical Pharmacology in Gastroenterology and Hepatology 2010 ·American Journal of Therapeutics ·J Prandota	5
6	Recurrent Headache as the Main Symptom of Acquired Cerebral Toxoplasmosis in Nonhuman Immunodeficiency Virus-infected Subjects With no Lymphadenopathy 2007 ·American Journal of Therapeutics ·J Prandota	28
7	Limitations in the Clinical Usefulness of Single-Dose Pharmacokinetic Studies of Drugs and a Bayesian Approach for the Estimation of Kinetic Parameters 2004 ·American Journal of Therapeutics ·J Prandota	1
8	Urinary Tract Diseases Revealed after DTP Vaccination in Infants and Young Children 2004 ·American Journal of Therapeutics ·J Prandota	6
9	Possible Pathomechanisms of Sudden Infant Death Syndrome 2004 ·American Journal of Therapeutics ·J Prandota	69
10	Important Role of Prodromal Viral Infections Responsible for Inhibition of Xenobiotic Metabolizing Enzymes in the Pathomechanism of Idiopathic Reye's Syndrome, Stevens-Johnson Syndrome, Autoimmune Hepatitis, and Hepatotoxicity of the Therapeutic Doses of Acetaminophen Used in Genetically Predisposed Persons 2002 ·American Journal of Therapeutics ·J Prandota	20
11	Autoimmune hepatitis associated with the odour of a fish food proteins: A causal relationship or just a mere association? 2002 ·Allergologia et Immunopathologia ·J Prandota, (unknown)	4
12	Impaired Activation of the Fibrinolytic System in Children With Henoch-Sch??nlein Purpura: Beneficial Effect of Hydrocortisone Plus ??-Aminocaproic Acid Therapy on Disappearance Rate of Cutaneous Vasculitis and Fibrinolysis 2001 ·American Journal of Therapeutics ·J Prandota, (unknown), (unknown)	21
13	Plasma Proteinase Inhibitor Activity and Hemostasis Tests in Children With Nephrotic Syndrome. Effect of Prednisone Alone and Prednisone Plus ??-Aminocaproic Acid Treatment Regimens: A Preliminary Report 2001 ·American Journal of Therapeutics ·J Prandota, (unknown), (unknown), Leszek Noga	5
14	Unusual Distribution, Pharmacokinetics, and Metabolism of Some Drugs and Their Implications to Pharmacotherapy 2000 ·American Journal of Therapeutics ·J Prandota	7
15	Urographic percentile charts for vertical kidney mobility in childhood 1996 ·International Urology and Nephrology ·J Prandota, (unknown)	4
16	[A case of histiocytosis of Langerhans cells]. 1992 ·PubMed ·J Prandota, (unknown), (unknown)	1
17	Diuretic effect and disposition of furosemide in cystic fibrosis 1991 ·European Journal of Clinical Pharmacology ·J Prandota, I. J. Smith, Bettina C. Hilman, John T. Wilson	4
18	Pharmacokinetic, biliary excretion, and metabolic studies of¹⁴C-furosemide in the rat 1991 ·Xenobiotica ·J Prandota, Albert W. Pruitt	16
19	High doses of furosemide in children with acute renal failure 1991 ·International Urology and Nephrology ·J Prandota	8
20	Dosage regimen of cimetidine reviewed. Possible drug accumulation after multiple oral doses 1988 ·European Journal of Clinical Pharmacology ·J Prandota, I. J. Smith, John T. Wilson	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact